DeepMed Research

ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Completed

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)

Interventions: Drug: linaclotide

First Posted Date: 2018-03-21

Last Posted Date: 2024-10-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 2475

Registration Number: NCT03471728

Locations: 🇯🇵
Site JP00003, Iwate, Japan
🇯🇵
Site JP00039, Kochi, Japan
🇯🇵
Site JP00028, Hyogo, Japan

and more 44 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ESN364
Drug: Placebo

First Posted Date: 2018-02-19

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 44

Registration Number: NCT03436849

Locations: 🇯🇵
Site JP00001, Fukuoka, Japan

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

Completed

Conditions: Bipolar Disorder
Depression

Interventions: Drug: Quetiapine

First Posted Date: 2018-01-19

Last Posted Date: 2024-10-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 369

Registration Number: NCT03403790

Locations: 🇯🇵
Site JP00005, Akita, Japan
🇯🇵
Site JP00038, Ehime, Japan
🇯🇵
Site JP00007, Fukushima, Japan

and more 44 locations

ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: ASP8302

First Posted Date: 2017-12-05

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 56

Registration Number: NCT03361540

Locations: 🇯🇵
Site JP00001, Toshima, Tokyo, Japan

Development of Visual Function Evaluation Method

Completed

Conditions: Retinitis Pigmentosa

First Posted Date: 2017-09-13

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 18

Registration Number: NCT03281005

Locations: 🇯🇵
Site JP00001, Meguro-ku, Tokyo, Japan

A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: ASP5094
Drug: Placebo
Other: Methotrexate therapy

First Posted Date: 2017-08-22

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 66

Registration Number: NCT03257852

Locations: 🇯🇵
Site JP00016, Ichinomiya, Japan
🇯🇵
Site JP00005, Kitamoto, Japan
🇯🇵
Site JP00011, Oita, Japan

and more 28 locations

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2

Completed

Conditions: Urologic Neoplasms
Renal Pelvis Neoplasms
Urinary Bladder Neoplasms
Urothelial Cancer
Urethral Neoplasms
Carcinoma, Transitional Cell
Ureteral Neoplasms

Interventions: Drug: Enfortumab vedotin

First Posted Date: 2017-07-17

Last Posted Date: 2024-08-27

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 219

Registration Number: NCT03219333

Locations: 🇺🇸
Johns Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 78 locations

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ASP8062
Drug: Placebo

First Posted Date: 2017-06-12

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 36

Registration Number: NCT03183739

Locations: 🇯🇵
Site JP00001, Sumida, Tokyo, Japan

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3

Active, not recruiting

Conditions: AML With FLT3 Mutation

Interventions: Drug: Gilteritinib
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: G-CSF
Drug: Fludarabine

First Posted Date: 2017-06-09

Last Posted Date: 2025-05-09

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 276

Registration Number: NCT03182244

Locations: 🇨🇳
Site CN123, Huangpu Qu, China
🇨🇳
Site CN117, Jinan, China
🇨🇳
Site CN133, Lanzhou, China

and more 46 locations

A Dose-finding Study of ASP4070

Phase 2

Completed

Conditions: Rhinitis, Allergic, Seasonal

Interventions: Drug: ASP4070
Drug: Placebo

First Posted Date: 2017-04-05

Last Posted Date: 2024-11-26

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 150

Registration Number: NCT03101267

Locations: 🇯🇵
Site JP00001, Shinjuku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy